Skip to main content
SpringerLink
Log in

Post-Fracture Prescribed Calcium and Vitamin D Supplements Alone or, in Females, with Concomitant Anti-Osteoporotic Drugs is Associated with Lower Mortality in Elderly Hip Fracture Patients

A Prospective Analysis

  • Original Research Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Background

Several studies have shown excess mortality among hip fracture patients compared with the normal population of the same age. Finnish guidelines for medical treatment of hip fracture patients recommend anti-osteoporosis medication and the daily concomitant use of prescribed calcium and vitamin D supplements. However, whether post-fracture use of calcium and vitamin D supplements is associated with survival in such patients has not been evaluated.

Objective

To study the association between survival in hip fracture patients and patients’ sex and age, pre-fracture vitamin D status, American Society of Anesthesiologists — Physical Status (ASA-PS) class, type of fracture and post-fracture use of prescribed calcium plus vitamin D and anti-osteoporotic medication.

Methods

The study population was 221 hip fracture patients primarily treated in acute care for a new hip fracture in 2003–4 in two Finnish hospitals. After a median of 27.5 months from the fracture, a questionnaire was sent to all patients who were still alive at the time (n = 137). The patients were queried about their use of prescribed calcium plus vitamin D supplementation and of anti-osteoporotic drugs. The follow-up time for use of anti-osteoporotic medication and prescribed calcium and vitamin D was 19.5–36 months (median 27.5 months). Data on the use of prescribed calcium plus vitamin D supplementation and anti-osteoporotic drugs were checked against information on reimbursement of drug prescriptions held by the Finnish Social Insurance Institution. A total of 4 years’ (48 months’) survival data for all patients in the study population was also obtained, with the dates of patient deaths being checked against Official National and Regional population statistics. Patient survival was analysed using both the Bayesian multivariate analysis and the life table method.

Results

In the multivariate analysis, the combination of variables that best explained post-fracture survival was as follows: age <80 years; ASA-PS class 1–2 (ASA-PS class 1 and 2 data were combined in calculations); post-fracture use of prescribed calcium plus vitamin D supplements concomitantly with anti-osteoporotic drugs; post-fracture use of prescribed calcium plus vitamin D supplements; post-fracture use of anti-osteoporotic drugs only; and type of fracture (femoral neck or subtrochanteric). This model correctly predicted 74% of cases. At 36 months, we observed a 36% reduction in deaths in females who used prescribed calcium plus vitamin D supplementation and a corresponding 43% reduction in males. Survival of females who used anti-osteoporotic drugs concomitantly was even greater (43% reduction in deaths) over the entire follow-up period. Excess mortality was highest in females and males who used neither anti-osteoporotic drugs nor prescribed calcium and vitamin D.

Conclusion

Our results indicate a potential relationship between reduced mortality and post-fracture use of prescribed calcium plus vitamin D supplementation and, in females, concomitant use of anti-osteoporotic drugs. However, further investigations are needed to understand the reason for the reduction in the risk of death. Population-based, randomized, placebo-controlled trials with total mortality as the main endpoint should be conducted to verify our results.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Table I
Table II
Table III
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Gardner MJ, Flik KR, Mooar P, et al. Improvement in the undertreatment of osteoporosis following hip fracture. J Bone Joint Surg Am 2002 Aug; 84(8): 1342–8

    PubMed  Google Scholar 

  2. Juby AG, De Geus-Wenceslau CM. Evaluation of osteoporosis treatment in seniors after hip fracture. Osteoporos Int 2002 Mar; 13(3): 205–10

    Article  PubMed  CAS  Google Scholar 

  3. Cadarette SM, Katz JN, Brookhart MA, et al. Trends in drug prescribing for osteoporosis after hip fracture, 1995–2004. J Rheumatol 2008; 35: 319–26

    PubMed  Google Scholar 

  4. Blomfeldt R, Törnkvist H, Ponzer S, et al. Internal fixation versus hemiarthroplasty for displaced fractures of the femoral neck in elderly patients with severe cognitive impairment. J Bone Joint Surg Br 2005 Apr; 87(4): 523–9

    Article  PubMed  CAS  Google Scholar 

  5. Tidermark J, Ponzer S, Svensson O, et al. Internal fixation compared with total hip replacement for displaced femoral neck fractures in elderly: a randomised, controlled trial. J Bone Joint Surg Br 2003 Apr; 85(3): 380–8

    Article  PubMed  CAS  Google Scholar 

  6. Trombetti A, Herrmann F, Hoffmeyer P, et al. Survival and potential years of life lost after hip fracture in men and age-matched women. Osteoporos Int 2002 Sep; 13(9): 731–7

    Article  PubMed  CAS  Google Scholar 

  7. Adler RA. Epidemiology and pathophysiology of osteoporosis in men. Curr Osteoporos Rep 2006 Sep; 4(3): 110–5

    Article  PubMed  Google Scholar 

  8. Nurmi I, Narinen A, Lüthje P, et al. Functional outcome and survival after hip fracture in elderly: a prospective study in 106 consecutive patients. J Orthopaed Traumatol 2004; 4: 7–14

    Article  Google Scholar 

  9. Endres HG, Dasch B, Lungenhausen M, et al. Patients with femoral or distal forearm fracture in Germany: prospective observational study on health care situation outcome. BMC Public Health 2006 Apr; 6: 87

    Article  PubMed  Google Scholar 

  10. Pitto RP. The mortality and social prognosis of hip fractures: a prospective multifactorial study. Int Orthop 1994 Apr; 18(2): 109–13

    Article  PubMed  CAS  Google Scholar 

  11. Katelaris AG, Cumming RG. Health status before and mortality after hip fracture. Am J Public Health 1996 Apr; 86(4): 557–9

    Article  PubMed  CAS  Google Scholar 

  12. Jacobsen SJ, Goldberg J, Miles TP, et al. Race and sex differences in mortality following fracture of the hip. Am J Public Health 1992 Aug; 82(8): 1147–50

    Article  PubMed  CAS  Google Scholar 

  13. Kreutzfeldt J, Haim M, Bach E. Hip fracture among the elderly in a mixed urban and rural population. Age Ageing 1984 Mar; 13(2): 111–9

    Article  PubMed  CAS  Google Scholar 

  14. Forsén L, Sogaard AJ, Meyer HE, et al. Survival after hip fracture: short- and long-term excess mortality according to age and gender. Osteoporos Int 1999; 10(1): 73–8

    Article  PubMed  Google Scholar 

  15. Robbins JA, Biggs ML, Cauley J. Adjusted mortality after hip fracture: from the Cardiovascular Health Study. J Am Geriatr Soc 2006 Dec; 54(12): 1885–91

    Article  PubMed  Google Scholar 

  16. Schrøder HM, Erlandsen M. Age and sex as determinants of mortality after hip fractures: 3,895 patients followed for 2.5-18.5 years. J Orthop Trauma 1993; 7(6): 525–31

    Article  PubMed  Google Scholar 

  17. Nurmi I, Kaukonen JP, Lüthje P, et al. Half of the patients with an acute hip fracture suffer from hypovitaminosis D: a prospective study in southeastern Finland. Osteoporos Int 2005; 16: 2018–24

    Article  PubMed  CAS  Google Scholar 

  18. Owens WD, Felts JA, Spitznagel Jr EL. ASA physical status classification: a study consistency of ratings. Anaesthesiology 1978 Oct; 49(4): 239–43

    Article  CAS  Google Scholar 

  19. Lüthje P, Nurmi-Lüthje I, Kaukonen JP, et al. Under-treatment of osteoporosis following hip fracture in the elderly. Arch Gerontol Geriatr Epub 2008 Aug 13

    Google Scholar 

  20. Aine R, Kataja M, Alavaikko M. Prognostic factors for non-cleaved follicular center-cell lymphomas and immunoblastic sarcoma: a Bayesian approach. Scand J Haematol 1984 May; 32(5): 457–87

    Google Scholar 

  21. Hakulinen T. On long-term relative survival rates. J Chron Dis 1977 Jul; 30(7): 431–43

    Article  PubMed  CAS  Google Scholar 

  22. Causes of death 1969–2007. Helsinki: Official Statistics of Finland, 2008 Dec 14 [online]. Available from URL: http://pxweb2.stat.fi/database/StatFin/ter/ksyyt/ksyyt_en.asp [Accessed 2008 Mar 30]

  23. Zethraeus N, Borgström F, Ström O, et al. Cost-effectiveness of the treatment and prevention of osteoporosis: a review of the literature and a reference model. Osteoporos Int 2007; 18: 9–23

    Article  PubMed  CAS  Google Scholar 

  24. Carpintero P, Lopez P, Leon F, et al. Men with hip fractures have poorer nutritional status and survival than women. Acta Orthop 2005 Jun; 76(3): 331–5

    PubMed  Google Scholar 

  25. Chapuy MC, Preziosi P, Maamer M, et al. Prevalence of vitamin D insufficiency in adult normal population. Osteoporosis Int 1997; 7: 439–43

    Article  CAS  Google Scholar 

  26. Heaney RP, Dowell MS, Hale CA, et al. Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D. J Am Coll Nutr 2003; 22: 142–6

    PubMed  CAS  Google Scholar 

  27. Lo JC, Pressman AR, Omar MA, et al. Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos Int 2006; 17(6): 922–8

    Article  PubMed  CAS  Google Scholar 

  28. Cree MW, Juby AG, Carriere KC. Mortality and morbidity associated with osteoporosis drug treatment following hip fracture. Osteoporos Int 2003; 14(9): 722–9

    Article  PubMed  Google Scholar 

  29. Lyles KW, Colon-Erneric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007 Nov; 357(18) 1799–809

    Article  PubMed  CAS  Google Scholar 

  30. Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ 2003 Mar; 326(7387): 469–72

    Article  PubMed  CAS  Google Scholar 

  31. Heaney RP. Long-latency deficiency disease: insights from calcium and vitamin D. Am J Clin Nutr 2003 Nov; 78(5): 912–9

    PubMed  CAS  Google Scholar 

  32. Palmieri GMA, Nutting DF, Bhattacharya SK, et al. Parathyroid ablation in dystrophic hamsters. J Clin Invest 1981; 68: 646–54

    Article  PubMed  CAS  Google Scholar 

  33. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007 May; 356(18): 1809–22

    Article  PubMed  CAS  Google Scholar 

  34. Autier P, Gandini S. Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. Arch Intern Med 2007 Sep; 167(16): 1730–7

    Article  PubMed  CAS  Google Scholar 

  35. Rodan G, Reszka A, Golub E, et al. Bone safety of long-term bisphosphonate treatment. Curr Med Res Opin 2004; 20: 1291–300

    Article  PubMed  CAS  Google Scholar 

  36. Lasseter KC, Porras AG, Denker A, et al. Pharmacokinetic considerations in determining the terminal elimination half-lives of bisphosphonates. Clin Drug Investig 2005; 25(2): 107–14

    Article  PubMed  CAS  Google Scholar 

  37. Thomas M, Lloyd-Jones DM, Thadhanai RI, et al. Hypovitaminosis D in medical inpatients. N Engl J Med 1998; 3338: 777–83

    Article  Google Scholar 

  38. Nurmi-Lüthje I, Kaukonen JP, Lüthje P, et al. Use of benzodiazepines and benzodiazepine-related drugs among 223 patients with an acute hip fracture in Finland: comparison of benzodiazepine findings in medical records and laboratory assays. Drugs Aging 2006; 23(1): 27–37

    Article  PubMed  Google Scholar 

  39. Kaukonen JP, Nurmi-Lüthje I, Lüthje P, et al. Acute alcohol use among patients with acute hip fractures: a descriptive incidence study in southeastern Finland. Alcohol Alcohol 2006; 41(3): 345–8

    PubMed  Google Scholar 

  40. Holick MF, Garabedian M. Vitamin D: photobiology, metabolism, mechanism of action, and clinical applications. In: Favus MJ, editor. Primer on the metabolic bone diseases and disorders of mineral metabolism, 6th ed. Washington, DC: American Society for Bone and Mineral Research, 2006: 106–14

    Google Scholar 

Download references

Acknowledgements

The study was supported by grants from the EVO (Erityisvaltionosuus) foundations of the Kymenlaakso and Päijät-Häme healthcare districts and the Kymi Ltd 100-years Foundation. Dr Nurmi-Lüthje has acted as a consultant (speaker at educational sessions) for Merck. Dr Lüthje has been a speaker for Merck, Novartis and sanofi-aventis and has participated in international conferences on osteoporosis sponsored by Merck, Novartis and sanofi-aventis. Dr Kataja has acted as a statistics consultant to Sandoz and Novartis. The other authors have no conflicts of interest that are directly relevant to the content of this study.

Author information

Authors and Affiliations

  1. Department of Public Health, University of Helsinki, Helsinki, Finland

    Ilona Nurmi-Lüthje

  2. Health Centre of Kouvola, Kouvola, Finland

    Ilona Nurmi-Lüthje

  3. Kuusankoski Regional Hospital, Kuusankoski, Finland

    Peter Lüthje, Salla Kuurne & Kalevi Karjalainen

  4. Päijät-Häme Central Hospital, Lahti, Finland

    Juha-Pekka Kaukonen & Helena Naboulsi

  5. National Public Health Institute, Helsinki, Finland

    Matti Kataja

Authors
  1. Ilona Nurmi-Lüthje
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter Lüthje
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Juha-Pekka Kaukonen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Matti Kataja
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Salla Kuurne
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Helena Naboulsi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kalevi Karjalainen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ilona Nurmi-Lüthje.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nurmi-Lüthje, I., Lüthje, P., Kaukonen, JP. et al. Post-Fracture Prescribed Calcium and Vitamin D Supplements Alone or, in Females, with Concomitant Anti-Osteoporotic Drugs is Associated with Lower Mortality in Elderly Hip Fracture Patients. Drugs Aging 26, 409–421 (2009). https://doi.org/10.2165/00002512-200926050-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200926050-00005

Keywords

Search

Navigation